Cerity Partners LLC increased its stake in GSK PLC Sponsored ADR (NYSE:GSK - Free Report) by 6.4% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 445,680 shares of the pharmaceutical company's stock after purchasing an additional 26,678 shares during the period. Cerity Partners LLC's holdings in GSK were worth $17,266,000 as of its most recent filing with the Securities and Exchange Commission.
A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in GSK. Dodge & Cox lifted its position in GSK by 0.5% during the 4th quarter. Dodge & Cox now owns 68,440,912 shares of the pharmaceutical company's stock worth $2,314,672,000 after buying an additional 353,749 shares in the last quarter. FMR LLC lifted its position in GSK by 82.1% during the 4th quarter. FMR LLC now owns 52,823,032 shares of the pharmaceutical company's stock worth $1,786,475,000 after buying an additional 23,814,104 shares in the last quarter. Primecap Management Co. CA lifted its position in GSK by 70.1% during the 4th quarter. Primecap Management Co. CA now owns 25,261,660 shares of the pharmaceutical company's stock worth $854,349,000 after buying an additional 10,407,905 shares in the last quarter. Price T Rowe Associates Inc. MD lifted its position in GSK by 0.5% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 7,566,922 shares of the pharmaceutical company's stock worth $255,914,000 after buying an additional 35,134 shares in the last quarter. Finally, Mondrian Investment Partners LTD lifted its position in GSK by 17.6% during the 4th quarter. Mondrian Investment Partners LTD now owns 5,838,384 shares of the pharmaceutical company's stock worth $205,920,000 after buying an additional 874,004 shares in the last quarter. 15.74% of the stock is owned by institutional investors and hedge funds.
Wall Street Analyst Weigh In
A number of equities analysts recently weighed in on the stock. Hsbc Global Res upgraded shares of GSK to a "strong sell" rating in a report on Monday, April 28th. Wall Street Zen downgraded shares of GSK from a "buy" rating to a "hold" rating in a research note on Friday, May 30th. Berenberg Bank reiterated a "hold" rating on shares of GSK in a research note on Tuesday, June 3rd. Finally, BNP Paribas initiated coverage on shares of GSK in a research note on Tuesday, April 15th. They issued a "neutral" rating and a $35.25 target price for the company. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, GSK currently has a consensus rating of "Hold" and a consensus target price of $37.38.
View Our Latest Stock Analysis on GSK
GSK Stock Performance
NYSE:GSK traded down $0.48 during mid-day trading on Tuesday, hitting $37.81. The stock had a trading volume of 8,569,145 shares, compared to its average volume of 5,016,137. GSK PLC Sponsored ADR has a twelve month low of $31.72 and a twelve month high of $44.67. The stock has a market cap of $77.41 billion, a price-to-earnings ratio of 19.49, a PEG ratio of 1.54 and a beta of 0.50. The company's 50 day simple moving average is $38.97 and its 200 day simple moving average is $37.33. The company has a debt-to-equity ratio of 1.21, a quick ratio of 0.58 and a current ratio of 0.87.
GSK (NYSE:GSK - Get Free Report) last released its quarterly earnings results on Wednesday, April 30th. The pharmaceutical company reported $1.13 earnings per share for the quarter, beating the consensus estimate of $1.08 by $0.05. The firm had revenue of $10.06 billion for the quarter, compared to analysts' expectations of $7.52 billion. GSK had a net margin of 9.89% and a return on equity of 48.82%. The business's revenue was up 2.1% on a year-over-year basis. During the same period in the prior year, the firm earned $0.43 EPS. On average, equities research analysts forecast that GSK PLC Sponsored ADR will post 4.14 earnings per share for the current year.
GSK Increases Dividend
The business also recently declared a quarterly dividend, which was paid on Thursday, July 10th. Shareholders of record on Friday, May 16th were issued a $0.4216 dividend. This is a boost from GSK's previous quarterly dividend of $0.39. This represents a $1.69 annualized dividend and a yield of 4.46%. The ex-dividend date of this dividend was Friday, May 16th. GSK's dividend payout ratio is currently 88.14%.
GSK Profile
(
Free Report)
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.
Featured Articles
Before you consider GSK, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and GSK wasn't on the list.
While GSK currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
